Medicus Pharma (MDCX) Q3 2026 earnings review
Medicus licenses a Pfizer drug, but its usable cash shrinks
Medicus Pharma, a drug developer with no sales, bought rights to a Pfizer cancer drug while its cash ran low. The licence cost a net $10 million, most of a $15 million quarterly loss. Without that charge, the loss shrank by about 29% by our math, helped by a credit on its prostate drug Teverelix.
| Quarterly loss, excluding licence charges | $5.2M −29% from a year ago |
|---|---|
| Reported quarterly loss | $15.2M $16.0M a year ago |
| Cash it can spend freely | $5.0M $8.7M at the end of 2025 |
| Spending outlook | Cuts promised no figure given |
⚖️ Verdict: 🔴 Bearish
The story got worse, because Medicus now owes more than it owns and its own filing doubts it can last a year. Its lender can start demanding monthly repayments in December. The good news: the Pfizer drug and a planned separate listing for SkinJect, its skin cancer patch, give investors something to fund.
The question now is whether Medicus can raise money before a $15 million Pfizer payment falls due next September. Either the SkinJect deal and partners bring cash, or Medicus keeps selling new shares. Its decision by June on whether to keep the licence will settle it.
🐂 Bull Case
Medicus Now Controls a Pfizer Cancer Drug
CD228V is an antibody-drug conjugate, a medicine that carries a toxic payload to cancer cells marked by a protein called CD228. In September Medicus took an exclusive worldwide licence to it from Pfizer. Chief executive Raza Bokhari then made the drug the main priority, starting with melanoma that no longer responds to other treatment.
The drug already has US clearance for tests in people, and Bokhari said Pfizer had treated 11 patients with this version. Pfizer also contributed $2 million toward development and kept an option to fund later trials. So Medicus paid a net $10 million for a drug in clinical testing.
Bokhari told investors "we believe CD228V has the potential to achieve an objective response rate exceeding 30% in melanoma". In plain words, tumours would shrink in more than three of every ten patients. But he also said detailed results from the earlier Seagen version "have not yet been publicly disclosed", so outsiders cannot test that goal.
What to watch: the date Medicus gives the first patient the drug. The licence requires another $15 million payment next September unless Medicus cancels first, and dosing a patient narrows that exit. An early first dose would show Medicus committing money it has not yet raised.
A Listing Deal Could Fund the SkinJect Patch
SkinJect is a skin patch with tiny dissolving needles that deliver a chemotherapy drug into skin cancers. In September Medicus limited it to Gorlin syndrome, a rare inherited disease that causes many basal cell skin cancers.
On November 4 SkinJect signed a non-binding letter with a special purpose acquisition company, a listed shell that merges with a private firm. The letter puts SkinJect's worth at about $135 million before new money. Chief executive Raza Bokhari wants Medicus to keep majority ownership, and the deal would bring "concurrent equity financing" for the Gorlin study.
That matters because the merger would move the study's funding outside Medicus, which is short of cash. One open point remains: the FDA has paused its review of SkinJect's rare-disease designations until Medicus sends more information.
What to watch: a signed merger agreement before the closing Bokhari expects in the first half of 2027. A signed deal with committed money would move the Gorlin study's cost off Medicus's own budget.
🐻 Bear Case
Medicus Has Cash for Only a Few Months
Medicus ended September with $13.1 million, but $8.1 million of it sits in an account its lender, Streeterville Capital, controls. Its quarterly filing states that "substantial doubt exists about the Company's ability to continue as a going concern". In plain words, Medicus may not last a year without new money.
By our math, Medicus used about $2.4 million a month in the first nine months, leaving out the Pfizer licence payment. At that pace, the $5.0 million it can spend freely covers about two months. Finance chief Carolyn Bonner promised "a substantial reduction in our operating expenses in the coming quarters".
- Secured notes owed to Streeterville: about $22.1 million of principal, due November 2027
- Monthly repayments the lender can demand from late December: up to $600,000
- Share of each new share sale the lender can claim: 25%
- Next payment to Pfizer for CD228V, its licensed cancer drug: $15 million in September 2027
So even lower costs leave Medicus short, because the lender takes cash first: each new dollar raised brings only 75 cents to the drug work.
What to watch: unrestricted cash at the end of December, in the annual report. A figure near zero would mean the SkinJect deal or a partner payment must arrive before CD228V trials can start.
Lower Costs Rest Partly on a Teverelix Credit
Leaving out the Pfizer licence charge, Medicus spent $4.5 million to run the business in the third quarter. By our math that is about a third less than a year ago, and finance chief Carolyn Bonner said deeper cuts are coming.
Teverelix, the prostate cancer drug, recorded minus $1.4 million in clinical and manufacturing costs, which lowered the total. Administrative costs halved, but the filing links this to a "decrease in the allocation of certain personnel costs to general and administrative expenses". Research salaries rose fivefold at the same time.
- Spending without the Pfizer charge and the Teverelix entry: down about 13% by our math
- Administration plus research salaries: down about 6%
What to watch: fourth-quarter spending without licence charges, in the annual report. A level near $5.8 million, the figure without the Teverelix entry, would mean the cut Bonner described has not yet begun.
Share Count Grew More Than Fourfold in a Year
Medicus pays for its research mostly by selling new shares through an at-the-market programme, which lets it sell small amounts on the exchange at any time. That programme brought in $17.8 million before costs in the first nine months.
- Shares outstanding: 1.85 million, more than four times the count a year earlier
- Share count growth from last quarter: 54%, a third straight quarter above 50%
- Options and warrants: about 286,000 further shares
The October 50-to-1 share consolidation does not change these comparisons, because Medicus restated all periods. Loss per share fell 79% mostly because the share count rose, while the reported loss shrank only 5%.
What to watch: the year-end share count in the annual report. Another quarterly rise near 50% would mean existing owners keep paying for the trials with a smaller slice of the company.
👓 Other Themes
Medicus Redesigns Teverelix Study for a Partner
On September 29 Medicus sent the FDA a new study plan for Teverelix, its hormone-blocking drug for advanced prostate cancer. The study would start with about 80 patients and grow to about 608 if early results meet set targets. Chief executive Raza Bokhari said drug manufacturing "hit some snags" and expects supply early next year. Medicus wants a partner to pay for the study.
💲 Other KPIs
Research spending rose 86% in the first nine months. Teverelix, the prostate drug Medicus bought last year, added $2.6 million of outside costs. Staff costs in research tripled, while SkinJect's outside costs dropped after its Phase 2 study ended.
Borrowing now costs the drug developer money: net interest came to a $0.71 million expense, against $0.01 million of income a year ago. The secured notes sold in May carry rates of up to 8.75%. Most of that interest accrues until repayment, so it adds to the debt instead of draining cash today.
Equity turned negative: liabilities of $25.0 million now exceed assets. At the end of 2025 it stood just above zero. The secured notes drove the swing, and Medicus booked the Pfizer licence as an expense, so the deal added no asset to the balance sheet.
🔮 Guidance
New. Finance chief Carolyn Bonner told investors she expects running costs to fall substantially, but gave no figure. The plan puts new money into CD228V only, while SkinJect and Teverelix get essential support until partners arrive. Third-quarter spending already benefited from a Teverelix credit, so the fourth quarter is the first clean test.
New. Bokhari put the cost of taking SkinJect to a new drug application at about $3 million. He spread that over the next two years, which by our math means roughly $0.4 million a quarter. SkinJect's outside costs ran at $0.5 million in the third quarter, so the planned pace sits slightly below today's.
New. Bokhari expects the SkinJect merger with an unnamed listed shell company to close in the first half of 2027. The letter of intent binds neither side, so Medicus still needs a signed agreement, the financing and shareholder votes. Until then, the parent will keep paying for the Gorlin study's preparation itself.
❓ Key Questions
How many months will Medicus's spendable cash last?
Cash Medicus can use freely stood at $5.0 million, and its lender can demand monthly repayments from December. Investors need the planned quarterly spending after the promised cuts to judge whether money runs out before trials start.
Will Medicus pay Pfizer $15 million in 2027?
Medicus can cancel the licence by June 4, 2027 if no patient has received CD228V. The answer depends on financing it does not yet have, so the funding plan for that payment matters.
What did the earlier 88-patient CD228 study show?
Bokhari based a response-rate goal above 30% in melanoma on these data, but said nobody has published the detailed findings. Shared results would let outsiders test that goal.
When will the first melanoma patient receive CD228V?
The first dose starts a costly trial and limits Medicus's right to leave the licence. Chief medical officer Faisal Mehmud said the team is still building the development plan, about 60 days after signing.
Did Medicus meet Nasdaq's November 16 listing test?
The filing gave Medicus until November 16 to regain compliance with a Nasdaq market-value standard. A delisting would count as a trigger event under its notes, which lets the lender raise the balance owed.